Company Analysis

Conduit Pharmaceuticals Inc. CDT

A comprehensive view of key metrics, scores, and financial health for Conduit Pharmaceuticals Inc.

Overview of Conduit Pharmaceuticals Inc.

CDT NCM

Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap

Conduit Pharmaceuticals Inc. (CDT), is a Micro Cap company, in the Biotechnology industry, last closed at $0.08, about 0.0% overvalued vs fair value, -100.0% 1Y return, ranked 893/1145 in sector.

Metrics ROE 561.8% Div Yield 381.95%

USD 0.08

-14.89%

(Delayed)

• Vol 90d: 233.9%

Market Cap

$89,961

Enterprise Value

$479,961

Overall Score

View breakdown

Overall

Growth

Fair

Profitability

Good

Health

Weak

Efficiency

Weak

Valuation

Fair

Growth

Fair

Profitability

Good

Health

Weak

Efficiency

Weak

Valuation

Fair

Completeness: 88%

Confidence: 89%

Updated: Oct 24

Top Beats

Quick Facts

Website https://www.conduitpharma.com

HQ Naples, FL

Employees 6

Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data

Show more details

Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps

Cash on Hand

$1.5M

172.4%%

Total Revenue

Net Income

-$39.2M

-120.3%%

Operating Expense

$36.7M

142.7%%

Money Flow Bridge

You are currently seeing a limited view of the money flow waterfall.

See the full waterfall with all stages on Premium. Upgrade

Flow Direction: Money moves from left to right

Components: Breakdown shows composition of each stage

Industry-Specific: Biotech / Pre-Revenue

Data Quality Notes

⚠️ Critical: Cash runway under 12 months - financing likely needed soon
⚠️ Company is distributing cash to shareholders while burning cash operationally
Note: Biotech companies are evaluated on cash runway and pipeline development, not profitability

Quality & Reliability Indicators

Cash Runway

1.2 months

Poor

Critical: Cash runway under 12 months

Locked Metric

Premium

Locked Metric

Premium

Locked Metric

Premium

Locked Metric

Premium

Locked Metric

Premium

Locked Metric

Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$8.1M

534.9% of Cash on Hand

Where It Leaks

Cash Flow Health healthy

Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.

Active Leaks

0/0

Improving

High Impact

Critical

Excellent! No significant cash flow leaks detected for this company.

Scores based on quantitative metrics and qualitative factors

Full moat analysis

Key strengths

ROIC Sustainably Above Peers ROIC at 97.3th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

Liquidity Concerns Liquidity is concerning (score 0.05), raising questions about short-term obligations.
Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data

—

Premium

Signals, strengths and risks for Pricing Power

Cost Advantage

Insufficient Data

—

Premium

Signals, strengths and risks for Cost Advantage

Customer Stickiness

Insufficient Data

—

Premium

Signals, strengths and risks for Customer Stickiness

Capital Efficiency

Strong

Premium

Signals, strengths and risks for Capital Efficiency

Resilience

Developing

Premium

Signals, strengths and risks for Resilience

Scale & Market Position

Insufficient Data

—

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked

Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

- vs peers

Key Signals

TSR -99.9% 0p

Strengths

No notable strengths identified for this axis.

Risks

Growth in bottom 20% of peers (percentile: 0)

Profitability

- vs peers

Key Signals

Strengths

Risks

Premium

Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

26th percentile vs peers

Key Signals

Strengths

Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Conduit Pharmaceuticals Inc..

WACC X.X%

X%XX%

Rev CAGR 5Y X.X%

-XX%XX%

Op Margin XX.X%

-XX%XX%

Adjust the sliders above to explore different valuation scenarios.

Unlock Premium

Reveal the full Scenario Theatre

See live sliders, narratives, and full Bear/Base/Bull outcomes.

Upgrade Now

Bear

- - -

- upside

Base

- - -

- upside

Bull

- - -

- upside

Fair Value Range Current: $-

$- $- $-

Conduit Pharmaceuticals Inc. CDT

Overview of Conduit Pharmaceuticals Inc.

Quick Facts

Next Events

Fair Value Snapshot

Engine Room Money Flow™

Flow Steps

Money Flow Bridge

Data Quality Notes

Quality & Reliability Indicators

Cash Runway

Locked Metric

Locked Metric

Locked Metric

Locked Metric

Locked Metric

Locked Metric

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Where It Leaks

Competitive Advantage Assessment

Key strengths

Key risks

Unlock full defense analysis

Pricing Power

Cost Advantage

Customer Stickiness

Capital Efficiency

Resilience

Scale & Market Position

Trade-Off Ledger™

Growth

Profitability

Safety

Two Futures

Actions & Info

Send Feedback